---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132783"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:05:35.181909+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM

## Summary
- Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.
- Four patients (40%) receiving repeated doses remain alive and progression-free for median over two years.
- No dose-limiting toxicities, CRS, or ICANS observed; most adverse events Grade 1-2.
- Phase 2 INB-400 trial shows preliminary mPFS of 10.8 months; additional data expected late 2025.

## SEC filing metadata
- accession: 0001193125-25-132783
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312525132783/0001193125-25-132783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312525132783/d945167d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132783
- JSON: https://secwatch.observer/filing/0001193125-25-132783.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.